Zurcher Kantonalbank Zurich Cantonalbank Has $221,000 Holdings in ZIOPHARM Oncology Inc. (ZIOP)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) by 933.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,918 shares of the biotechnology company’s stock after purchasing an additional 32,444 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ZIOPHARM Oncology were worth $221,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Adell Harriman & Carpenter Inc. bought a new stake in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $141,000. The Manufacturers Life Insurance Company boosted its position in ZIOPHARM Oncology by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock worth $649,000 after acquiring an additional 7,946 shares during the period. State Street Corp boosted its position in ZIOPHARM Oncology by 12.8% during the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after acquiring an additional 517,057 shares during the period. Tudor Investment Corp ET AL boosted its position in ZIOPHARM Oncology by 390.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 50,395 shares during the period. Finally, Voya Investment Management LLC lifted its holdings in shares of ZIOPHARM Oncology by 21.9% in the second quarter. Voya Investment Management LLC now owns 60,782 shares of the biotechnology company’s stock valued at $378,000 after buying an additional 10,913 shares during the period. Institutional investors own 40.25% of the company’s stock.

ZIOPHARM Oncology Inc. (NASDAQ ZIOP) opened at $4.00 on Thursday. ZIOPHARM Oncology Inc. has a 52-week low of $3.90 and a 52-week high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.11) earnings per share. sell-side analysts expect that ZIOPHARM Oncology Inc. will post -0.54 EPS for the current year.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the completion of the transaction, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is currently owned by insiders.

A number of brokerages have recently issued reports on ZIOP. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. BidaskClub lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.50 target price on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $12.58.

ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3079466/zurcher-kantonalbank-zurich-cantonalbank-has-221000-holdings-in-ziopharm-oncology-inc-ziop.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.